search
Back to results

Osteoarthritis Topical Treatment (ANTIPAIN)

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Phase 2
Locations
Switzerland
Study Type
Interventional
Intervention
Ibuprofen
placebo
Sponsored by
BioChemics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis focused on measuring Osteoarthritis, knee pain

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Main Inclusion Criteria:

  • Male or female patients aged at least 40 years.
  • Primary osteoarthritis in a single knee joint, grade II/III based on the Kellgren and Lawrence classification system.
  • Radiographic evidence consistent with osteoarthritis carried out within 6 months before screening.
  • pain is currently not adequately controlled with a simple analgesic or an NSAID OR would necessitate treatment, but is not yet treated.

Main Exclusion Criteria:

  • Concomitant presence of another type of continuous pain that is more severe in intensity in comparison with the osteoarthritis target joint pain
  • Osteoarthritis causing significant pain in any joint other than the identified knee, or contralateral knee (≥ 20 mm pain) as confirmed by a separate VAS at visit 1 for any other painful joint concerned.
  • Female patients who are pregnant or breast-feeding.

Sites / Locations

  • Rheumaklinik und Institut für Physikalische Medizin Universitätsspital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Ibuprofen

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Visual Analogue Scale (VAS) Pain scale

Secondary Outcome Measures

Full Information

First Posted
December 15, 2011
Last Updated
December 19, 2011
Sponsor
BioChemics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01496326
Brief Title
Osteoarthritis Topical Treatment
Acronym
ANTIPAIN
Official Title
A Pilot Study to Compare the Efficacy and Safety of a Novel 10% Ibuprofen Formulation Versus Placebo Alone Applied to the Knee in Patients With Painful Osteoarthritis of the Knee
Study Type
Interventional

2. Study Status

Record Verification Date
December 2011
Overall Recruitment Status
Completed
Study Start Date
February 2011 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
August 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BioChemics, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a phase 2a clinical trial performed to evaluate the efficacy of a topical treatment of ibuprofen compared to the use of a placebo topical treatment. A multi-center, double-blinded, randomized placebo controlled study. Study length: 14 days Dosing twice daily (b.i.d.)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
Osteoarthritis, knee pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
75 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ibuprofen
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Ibuprofen
Intervention Description
10% ibuprofen cream formulation at a dose of 200mg
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
2 grams of placebo cream for 14 days
Primary Outcome Measure Information:
Title
Visual Analogue Scale (VAS) Pain scale
Time Frame
14 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Main Inclusion Criteria: Male or female patients aged at least 40 years. Primary osteoarthritis in a single knee joint, grade II/III based on the Kellgren and Lawrence classification system. Radiographic evidence consistent with osteoarthritis carried out within 6 months before screening. pain is currently not adequately controlled with a simple analgesic or an NSAID OR would necessitate treatment, but is not yet treated. Main Exclusion Criteria: Concomitant presence of another type of continuous pain that is more severe in intensity in comparison with the osteoarthritis target joint pain Osteoarthritis causing significant pain in any joint other than the identified knee, or contralateral knee (≥ 20 mm pain) as confirmed by a separate VAS at visit 1 for any other painful joint concerned. Female patients who are pregnant or breast-feeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen Carter, Ph.D.
Organizational Affiliation
BioChemics, Inc.
Official's Role
Study Director
Facility Information:
City
Schaffhausen
ZIP/Postal Code
8200
Country
Switzerland
City
St. Gallen
ZIP/Postal Code
9000
Country
Switzerland
City
Zürich
ZIP/Postal Code
8001
Country
Switzerland
City
Zürich
ZIP/Postal Code
8050
Country
Switzerland
Facility Name
Rheumaklinik und Institut für Physikalische Medizin Universitätsspital
City
Zürich
ZIP/Postal Code
8091
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
24284856
Citation
Varadi G, Zhu Z, Blattler T, Hosle M, Loher A, Pokorny R, Frey D, Carter SG. Randomized clinical trial evaluating transdermal Ibuprofen for moderate to severe knee osteoarthritis. Pain Physician. 2013 Nov-Dec;16(6):E749-62.
Results Reference
derived

Learn more about this trial

Osteoarthritis Topical Treatment

We'll reach out to this number within 24 hrs